{"id":"pharmacokinetic-based-dosage-change","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pharmacokinetic-based dosage change refers to a clinical practice of individualizing drug doses according to measured or predicted drug concentrations and clearance rates in a patient. This approach aims to optimize therapeutic efficacy and minimize toxicity by accounting for patient-specific factors affecting drug absorption, distribution, metabolism, and elimination.","oneSentence":"This is a dosage adjustment strategy based on individual patient pharmacokinetic parameters rather than a specific drug entity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:41:27.436Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07357480","phase":"NA","title":"Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery","status":"RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2026-01-14","conditions":"Postoperative Delirium (POD), Postoperative Pain, PONV","enrollment":70},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT02805725","phase":"PHASE1, PHASE2","title":"Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2015-12","conditions":"Soft-tissue Sarcomas","enrollment":50},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT03235219","phase":"PHASE1","title":"A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":39},{"nctId":"NCT06761560","phase":"PHASE2, PHASE3","title":"Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yves Pastore","startDate":"2025-01-15","conditions":"Sickle Cell Disease (SCD)","enrollment":29},{"nctId":"NCT05043766","phase":"PHASE1","title":"Evaluation of Oral PF614 Relative to OxyContin (PF614-102)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-09-08","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT02956850","phase":"PHASE1","title":"A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-12-12","conditions":"Hepatitis B, Chronic","enrollment":160},{"nctId":"NCT06150833","phase":"PHASE3","title":"Efficacy and Safety and Pharmacokinetics of Boya IVIG","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2024-04-01","conditions":"Primary Immunodeficiency Disease","enrollment":50},{"nctId":"NCT06130527","phase":"NA","title":"Comparison of the Effects of Nicardipine and Remifentanil on Surgical Visual Field","status":"UNKNOWN","sponsor":"Erol Karaaslan","startDate":"2023-11-30","conditions":"Other Complications of Surgical and Medical Procedures","enrollment":64},{"nctId":"NCT04827056","phase":"PHASE1","title":"Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study","status":"COMPLETED","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2021-11-09","conditions":"Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)","enrollment":10},{"nctId":"NCT01572662","phase":"PHASE2","title":"Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-04-11","conditions":"Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia","enrollment":201},{"nctId":"NCT05836610","phase":"PHASE4","title":"Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates","status":"RECRUITING","sponsor":"Semmelweis University","startDate":"2021-09-21","conditions":"Hypoxic-Ischemic Encephalopathy, Asphyxia, Hypotension","enrollment":50},{"nctId":"NCT03439280","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2018-04-20","conditions":"Relapsed/Refractory, Multiple Myeloma","enrollment":50},{"nctId":"NCT04488770","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-24","conditions":"Urinary Tract Infections","enrollment":61},{"nctId":"NCT02053792","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-02-06","conditions":"Hemophilia B","enrollment":97},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256},{"nctId":"NCT03687073","phase":"PHASE1","title":"Trial of Indole-3-Carbinol and Silibinin","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-29","conditions":"Smoking","enrollment":21},{"nctId":"NCT01685411","phase":"NA","title":"Busulfan and Cyclophosphamide Followed By ALLO BMT","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT03038113","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-02-06","conditions":"Chronic Hepatitis B","enrollment":119},{"nctId":"NCT01859923","phase":"PHASE2","title":"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-07-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":37},{"nctId":"NCT02573168","phase":"NA","title":"Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2016-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":103},{"nctId":"NCT02502864","phase":"PHASE4","title":"Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-02-09","conditions":"Breast Cancer, Breast Cancer Female","enrollment":9},{"nctId":"NCT00625703","phase":"PHASE2","title":"Pharmacokinetics of Linezolid in Children With Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2010-12","conditions":"Cystic Fibrosis","enrollment":45},{"nctId":"NCT02412722","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2015-03-26","conditions":"Non-hematologic Malignancy","enrollment":61},{"nctId":"NCT02593851","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection","status":"TERMINATED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-12-04","conditions":"Respiratory Syncytial Virus Infections, Virus Diseases","enrollment":45},{"nctId":"NCT02919800","phase":"PHASE1","title":"A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2017-01-22","conditions":"Hemophilia A or B With Inhibitors","enrollment":32},{"nctId":"NCT02569710","phase":"PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2015-10-31","conditions":"Chronic Hepatitis C","enrollment":161},{"nctId":"NCT02896218","phase":"","title":"Therapeutic Monitoring of Vancomycin in Critical Ill Patients: a Registry","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2016-10","conditions":"Critically Ill","enrollment":400},{"nctId":"NCT03075410","phase":"PHASE1","title":"First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-04-02","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT03892122","phase":"PHASE4","title":"Efficacy and Stability of Dexmedetomidine Sedation Compared to Propofol Sedation in the Drug Induced Sleep Endoscopy","status":"UNKNOWN","sponsor":"Ospedale Monsignor R. Dimiccoli, Barletta","startDate":"2019-03-22","conditions":"Obstructive Sleep Apnea","enrollment":28},{"nctId":"NCT02119260","phase":"PHASE2","title":"A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-09","conditions":"Oedema, Pulmonary","enrollment":61},{"nctId":"NCT02751424","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-06-13","conditions":"Infections, Bacterial","enrollment":62},{"nctId":"NCT01364805","phase":"PHASE1","title":"New Treatment Option for Pancreatic Cancer","status":"COMPLETED","sponsor":"Jeanne Drisko, MD, CNS, FACN","startDate":"2011-04","conditions":"Pancreatic Cancer","enrollment":14},{"nctId":"NCT01540708","phase":"PHASE1","title":"A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-16","conditions":"Asthma","enrollment":36},{"nctId":"NCT02697370","phase":"PHASE4","title":"Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A","status":"COMPLETED","sponsor":"Hampshire Hospitals NHS Foundation Trust","startDate":"2013-04","conditions":"Severe Haemophilia A","enrollment":20},{"nctId":"NCT00891605","phase":"PHASE1","title":"Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2009-07","conditions":"Solid Tumors","enrollment":19},{"nctId":"NCT00459550","phase":"PHASE1","title":"A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-12","conditions":"Alzheimer's Disease","enrollment":50},{"nctId":"NCT00609245","phase":"PHASE4","title":"Effect of Valproic Acid Concentration on Photic Response","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2007-12","conditions":"Photosensitive Epilepsy","enrollment":13},{"nctId":"NCT01827657","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-28","conditions":"Hepatitis C","enrollment":31},{"nctId":"NCT01018628","phase":"PHASE1","title":"A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-12-07","conditions":"Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT02169583","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-12","conditions":"Infections, Respiratory Tract","enrollment":24},{"nctId":"NCT00519662","phase":"PHASE1","title":"Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sunesis Pharmaceuticals","startDate":"2007-08","conditions":"Advanced Solid Tumors","enrollment":32},{"nctId":"NCT00943111","phase":"PHASE3","title":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-09","conditions":"Gaucher Disease, Type 1","enrollment":160},{"nctId":"NCT02680600","phase":"NA","title":"Individualized Cefepime Dosing Study","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","startDate":"2014-03","conditions":"Antimicrobial Treatment","enrollment":20},{"nctId":"NCT01326767","phase":"PHASE3","title":"Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring","status":"COMPLETED","sponsor":"Central European Society for Anticancer Drug Research","startDate":"2011-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":366},{"nctId":"NCT02361138","phase":"PHASE1","title":"The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2013-12","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT02356224","phase":"PHASE1","title":"The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":84},{"nctId":"NCT02162199","phase":"PHASE1","title":"A Single Dose Study of Debio 1450 in Healthy Subjects","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2014-06","conditions":"Bacterial Infections","enrollment":48},{"nctId":"NCT00963768","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-06","conditions":"Diabetes Mellitus, Type 2","enrollment":116},{"nctId":"NCT00282256","phase":"PHASE2","title":"A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-01","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT00282243","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-02","conditions":"Liver Transplantation","enrollment":70},{"nctId":"NCT00282568","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-08","conditions":"Kidney Transplantation","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Factor VIII replacement therapy - non brand specific"],"phase":"marketed","status":"active","brandName":"Pharmacokinetic based dosage change","genericName":"Pharmacokinetic based dosage change","companyName":"Hampshire Hospitals NHS Foundation Trust","companyId":"hampshire-hospitals-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}